« Back to Record
Citation APA

Loi, S., Michiels, S., Salgado, R., Sirtaine, N., Jose, V., Fumagalli, D., Brown, D. N., Kellokumpu-Lehtinen, P.-L., Bono, P., Kataja, V., Desmedt, C., Piccart-Gebhart, M., Loibl, S., Untch, M., Denkert, C., Smyth, M. J., Joensuu, H., & Sotiriou, C. (2013). Tumor infiltrating lymphocytes (TILs) indicate trastuzumab benefit in early-stage HER2-positive breast cancer (HER2+ BC). online-only Supplement to Cancer Research Abstract session presented at San Antonio Breast Cancer Symposium - SABCS(36th: December 2013: San Antonio, Tx, USA)


Permalink

http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/153782

Loi, S., Michiels, S., Salgado, R., Sirtaine, N., Jose, V., Fumagalli, D., Brown, D. N., Kellokumpu-Lehtinen, P.-L., Bono, P., Kataja, V., Desmedt, C., Piccart-Gebhart, M., Loibl, S., Untch, M., Denkert, C., Smyth, M. J., Joensuu, H., & Sotiriou, C. (2013). Tumor infiltrating lymphocytes (TILs) indicate trastuzumab benefit in early-stage HER2-positive breast cancer (HER2+ BC). online-only Supplement to Cancer Research Abstract session presented at San Antonio Breast Cancer Symposium - SABCS(36th: December 2013: San Antonio, Tx, USA)